Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis (P12-4.002)
To evaluate efficacy and safety of TAK-861 in patients with narcolepsy type 1 (NT1) enrolled in a phase 2 trial and its ongoing long-term extension (LTE) study.
Authors
- Gert Jan Lammers (ORCID: https://orcid.org/0000-0003-4755-7060)
- Tina M. Olsson (ORCID: https://orcid.org/0000-0002-7351-9140)
- Philipp von Rosenstiel (ORCID: https://orcid.org/0000-0003-1709-1271)
- Shinichiro Tanaka (ORCID: https://orcid.org/0000-0003-4217-6859)
- Harisha Kadali
- Melissa Naylor (ORCID: https://orcid.org/0009-0006-7038-8276)
- Yeting Du
- Alice Cai (ORCID: https://orcid.org/0009-0000-0442-0801)
- Emmanuel Mignot (ORCID: https://orcid.org/0000-0002-6928-5310)
- Anson K. Abraham (ORCID: https://orcid.org/0000-0002-9579-7483)
- Yaming Hang
- Yves A Dauvilliers (ORCID: https://orcid.org/0000-0003-0683-6506)
- Giuseppe Plazzi
- Ellie Stukalin
Institutions
- University of Modena and Reggio Emilia (IT)
- Leiden University Medical Center (NL)
- Stanford Medicine (US)
- Takeda (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208433
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00